Latest News for: q32

Edit

Statement of Changes in Beneficial Ownership (Form 4) (Q32 Bio Inc)

Public Technologies 21 Mar 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10 ... Washington, D.C ... OMB Number. 3235-0287 ... 2 ... Q32 Bio Inc ... Q32 BIO INC., 830 WINTER STREET 3 ... Q32 BIO INC ... Q32 Bio Inc.
Edit

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Citizen Tribune 10 Mar 2026
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- ....
Edit

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update (Form 8-K) (Q32 Bio Inc)

Public Technologies 10 Mar 2026
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update ... WALTHAM, Mass.-March 10, 2026 - Q32 Bio Inc ... Q32 Bio expects to report 36-week topline results in mid-2026 ... Q32 Bio now has no remaining obligations to Amgen.
Edit

Initial Registration Statement for Employee Benefit Plan (Form S-8) (Q32 Bio Inc)

Public Technologies 10 Mar 2026
Q32 BIO INC ... Q32 Bio Inc ... Q32 Bio Inc ... Q32 Bio Inc ... This Registration Statement on Form S-8 (this "Registration Statement") is being filed by Q32 Bio Inc ... 99.1 Q32 Bio Inc ... 99.2 Q32 Bio Inc ... Q32 BIO INC ... Q32 Bio Inc.
Edit

Annual Report for Fiscal Year Ending 12-31, 2025 (Form 10-K) (Q32 Bio Inc)

Public Technologies 10 Mar 2026
Pursuant to the Merger Agreement, Merger Sub merged with and into Legacy Q32, with Legacy Q32 continuing as the surviving company and as a wholly-owned subsidiary of Homology (the "Merger").
Edit

Q32 Bio Announces $10.5 Million Registered Direct Offering (Form 8-K) (Q32 Bio Inc)

Public Technologies 17 Feb 2026
Q32 Bio Announces $10.5 Million Registered Direct Offering ... 17, 2026 /PRNewswire/ - Q32 Bio Inc ... The gross proceeds to Q32 Bio from this offering are expected to be approximately $10.5 million, before deducting certain offering expenses ... About Q32 Bio.
Edit

Supplemental Prospectus (Form 424B5) (Q32 Bio Inc)

Public Technologies 17 Feb 2026
and referred to herein as Legacy Q32), with Legacy Q32 continuing as the surviving entity as a wholly-owned subsidiary of Homology (the "Merger") ... and referred to herein as Legacy Q32), with ...
  • 1
×